Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for stroke
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on stroke or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on stroke and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Controlled trial of a home-care service for acute stroke patients. In a controlled trial of a home-care service available for the first 6 months after acute stroke, 440 patients received the new service and 417 patients were in the control group. The trial group used more hospital bed days, had a slightly higher admission rate, and did not show better emotional adjustment to stroke than the control group. There was no difference between the 2 groups in stress on relatives. Functional recovery
Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemicstroke. Results of an international randomized trial. The EC/IC Bypass Study Group. To determine whether bypass surgery would benefit patients with symptomatic atherosclerotic disease of the internal carotid artery, we studied 1377 patients with recent hemisphere strokes, retinal infarction, or transientischemicattacks who had atherosclerotic narrowing or occlusion of the ipsilateral internal carotid or middle (...) -Haenszel chi-square = 4.74), and those with persistence of ischemic symptoms after an internal-carotid-artery occlusion had been demonstrated (n = 287, chi-square = 4.04). This study thus failed to confirm the hypothesis that extracranial-intracranial anastomosis is effective in preventing cerebralischemia in patients with atherosclerotic arterial disease in the carotid and middle cerebral arteries.
Effectiveness of speech therapy for aphasic stroke patients. A randomised controlled trial. Aphasic stroke patients were randomly allocated to either a speech therapy group receiving treatment twice a week for 24 weeks or a no-treatment control group. Patients in both groups improved and there were no significant differences in language recovery between the 104 patients allocated to the treatment group and the 87 allocated to the no-treatment group. This treatment regimen, which (...) is representative of clinical practice, is ineffective for most aphasic stroke patients.
Nortriptyline treatment of post-stroke depression: a double-blind study. The efficacy of nortriptyline in the treatment of post-stroke depression was assessed by a double-blind study in thirty-four patients. Half of the patients had major depression. There was a significantly greater improvement in depression in patients treated with nortriptyline than in a similar group of placebo-treated patients. Depression was measured by the Hamilton depression scale, Zung depression scale, present state (...) examination, and an overall depression scale. Successfully treated patients had serum nortriptyline levels in the therapeutic range. Post-stroke depressions are common, severe, and longstanding, and the demonstrated efficacy of nortriptyline provides an important addition to the treatments available for stroke patients.
Randomised trial of pentoxifylline versus acetylsalicylic acid plus dipyridamole in preventing transientischaemicattacks. In a multicentre trial to compare the ability of a combination of acetylsalicylic acid and dipyridamole (1050 mg + 150 mg/day, group A) to prevent recurrence of transientischaemicattacks (TIA) with that of pentoxifylline (1200 mg/day, group B), 36 patients received the combination and 30 pentoxifylline. There was no statistically significant difference between the groups (...) as regards age, sex, blood pressure, site of origin of TIA, and incidence of other risk factors. The incidence of recurrent TIAs during 1 year of follow-up was 28% in group A and 10% in group B; this difference was significant (p less than 0.05). The incidence of permanent strokes was similar in the two groups but distinctly lower (4.5%) than that usually reported after untreated TIA.
A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. Five hundred and eighty-five patients with threatened stroke were followed in a randomized clinical trial for an average of 26 months to determine whether aspirin or sulfinpyrazone, singly or in combination, influence the subsequent occurrence of continuing transientischemicattacks, stroke or death. Eighty-five subjects went on to stroke, and 42 died. Aspirin reduced the risk (...) of continuing ischemicattacks, stroke or death by 19 per cent (P less than 0.05) and also reduced risk for the "harder," more important events of stroke or death by 31 percent (P less than 0.05), but this effect was sex-dependent: among men, the risk reduction for stroke or death was 48 per cent (P less than 0.005), whereas no significant trend was observed among women. For sulfinpyrazone, no risk reduction of ischemicattacks was observed, and the 10 per cent risk reduction of stroke or death
Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. A trial of subcutaneous low-dose heparin in the prevention of deep-vein thrombosis was carried out in elderly patients admitted to hospital after an acute stroke. A statistically significant reduction was observed in deep-vein thrombosis as assessed by isotope leg scanning.
Double-blind trial of glycerol therapy in early stroke. The effects of intravenous glycerol and intravenous dextrose were compared using a double-blind trial in twenty-seven patients with acute stroke. Administration continued for up to 6 days. A standard scoring system was used for neurological evaluation. There was no difference in mortality or in improvement in neurological score between the two groups.
Controlled trial of glycerol versus dexamethasone in the treatment of cerebral oedema in acute cerebralinfarction. 10 percent glycerol was given for 6 days to 30 patients who had had acute ischaemiccerebralinfarction, and the results were compared with those obtained after treating 31 similar patients with dexamethasone (16 mg. per 24 hours for 6 days). 1 patient treated with glycerol died of haemoglobinuria and acute renal failure. 6 patients treated with dexamethasone died--3 from cerebral (...) oedema and 3 from non-neurological complications (pulmonary embolism, myocardial infarction, and aspiration pneumonia). Improvement was significantly greater in the glycerol group after 8 and 15 days. No improvement was noted using either glycerol or dexamethasone in 7 patients with spontaneous intracerebral haemorrhage.
Age Factors Aged Arterial Occlusive Diseases epidemiology Blood Pressure Carotid Artery Diseases diagnostic imaging epidemiology surgery Cerebrovascular Disorders diagnostic imaging epidemiology surgery Continental Population Groups European Continental Ancestry Group Female Humans Hypertension epidemiology IschemicAttack, Transient epidemiology Male Middle Aged Neurologic Manifestations North Carolina Radiography Sex Factors Vascular Diseases epidemiology 1972 10 16 1972 10 16 0 1 1972 10 16 0 0 (...) Joint study of extracranial arterial occlusion. VI. Racial differences in hospitalized patients with ischemicstroke. 4678681 1973 03 05 2016 11 22 0098-7484 222 3 1972 Oct 16 JAMA JAMA Joint study of extracranial arterial occlusion. VI. Racial differences in hospitalized patients with ischemicstroke. 285-9 Heyman A A Fields W S WS Keating R D RD eng Clinical Trial Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 AIM IM Adult African Continental Ancestry Group
Treatment of acute stroke with dextran 40. 5394364 1969 11 26 2016 11 22 0098-7484 210 2 1969 Oct 13 JAMA JAMA Treatment of acute stroke with dextran 40. 293-8 Gilroy J J Barnhart M I MI Meyer J S JS eng Clinical Trial Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0 Carbon Isotopes 0 Dextrans AIM IM Blood Platelets cytology drug effects Blood Viscosity drug effects Carbon Isotopes Cerebrovascular Disorders drug therapy Dextrans therapeutic use Humans